Who is sponsoring NCT00592891?

NCT00592891 is sponsored by Paul G. Harch, M.D..

What drugs are being tested in NCT00592891?

Interventions in NCT00592891: Hyperbaric oxygen therapy.

What condition does NCT00592891 study?

NCT00592891 studies Adult and Pediatric Chronic Cerebral Disorders.

Is NCT00592891 still recruiting?

NCT00592891 is currently status unknown. Last updated 1 January 2015.

Last reviewed 2015-01-01 · How we verify

NCT00592891

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxygen Toxicity Effects Using Los-Pressure Hyperbaric Oxygen Therapy in the Treatment of Chronic Brain Injury

Status unknown Phase 1 Last updated 1 January 2015

What this trial tests

Phase 1 trial testing Hyperbaric oxygen therapy in Adult and Pediatric Chronic Cerebral Disorders in 45 participants. Status unknown.

Timeline

1 April 2002

Primary endpoint
1 December 2016

1 December 2016

Quick facts

Lead sponsor	Paul G. Harch, M.D.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	1 April 2002
Primary completion	1 December 2016
Estimated completion	1 December 2016
Sites	1 location across United States

Drugs / interventions tested

Hyperbaric oxygen therapy — full drug profile →

Conditions studied

Adult and Pediatric Chronic Cerebral Disorders — all drugs for Adult and Pediatric Chronic Cerebral Disorders →

Sponsor

Paul G. Harch, M.D. — full company profile →

Who can join

Eligibility, any sex, with Adult and Pediatric Chronic Cerebral Disorders. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Oxygen toxicity
Time frame: After completion of hyperbaric oxygen therapy

Sponsor's own description

Hypothesis: That HBOT can be toxic in the low-pressure range.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hyperbaric oxygen therapy as a potential treatment for post-traumatic stress disorder associated with traumatic brain injury.
Eve DJ, Steele MR, Sanberg PR, Borlongan CV. · · 2016 · cited 21× · PMID 27799776 · DOI 10.2147/ndt.s110126

Verify or expand the search:

Other trials of Hyperbaric oxygen therapy

Trials testing the same drug.

NCT06806345 — Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause · Phase 1, PHASE2 · recruiting
NCT06619808 — Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases · NA · recruiting
NCT05980195 — Cognitive Improvement After Carotid Stenting in Hyperbaric Oxygen Therapy Trial · NA · not yet recruiting
NCT06954376 — Hyperbaric Oxygen Therapy as a Neuroprotective Intervention in Pediatric Acquired Brain Injury With Cognitive Disability · NA · completed
NCT06954389 — Hyperbaric Oxygen Therapy as a Neuroprotective Modality in Pediatric Acquired Brain Injury With Motor Disability · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00592891 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Paul G. Harch, M.D.
Last refreshed: 1 January 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00592891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing